Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
Tuesday, February 13, 2024CymaBay Therapeutics Inc a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases today announced that the US Food and Drug Administration accepted its New Drug Application
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Monday, February 12, 2024Amylyx Pharmaceuticals Inc today announced it has completed enrollment of its Phase HELIOS trial of AMX sodium phenylbutyrate and taurursodiol for the treatment of Wolfram syndrome a rare genetic disease
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Friday, February 09, 2024BioNTech SE a nextgeneration immunotherapy company pioneering novel therapies for cancer and other serious diseases and Autolus Therapeutics plc a clinicalstage biopharmaceutical company
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
Thursday, February 08, 2024Telix Pharmaceuticals Limited today announces it has entered into an agreement to acquire QSAM Biosciences Inc and its lead investigational drug SamariumDOTMP QSAM is a United States based company developing therapeutic
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Wednesday, February 07, 2024Arvinas Inc and Pfizer Inc today announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of vepdegestrant for monotherapy
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
Wednesday, February 07, 2024Dyadic International Inc a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Tuesday, February 06, 2024MorphoSys AG today announced the company entered into a Business Combination Agreement with Novartis data AG and Novartis AG based on Novartis intention to submit a voluntary public takeover offer for all outstanding MorphoSys
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
Tuesday, February 06, 2024Exicure Inc a company that historically developed nucleic acid therapies and Bluejay Therapeutics Inc a private clinical stage biopharmaceutical company focused on viral and liver diseases announced today that Bluejay Therapeutics Inc
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Tuesday, February 06, 2024Global biotechnology leader CSL and Arcturus Therapeutics today announced the results of a followup analysis of a Phase study evaluating a booster dose of ARCT the worlds first approved selfamplifying messenger RNA
Azenta Launches the BioArc™ Ultra, a Breakthrough, Automated Solution for Efficient, Eco-Friendly Ultracold Sample Management
Monday, February 05, 2024Azenta Inc today announced the launch of the BioArc Ultra a breakthrough automated solution for highdensity ecofriendly ultracold sample management designed to provide a new level
